Jonathan Raa | Nurphoto | Getty Images
Neuralink, the neurotech startup led by Elon Musk, has exciting news. The company has announced that it will begin recruiting patients for its first in-human clinical trial, called the PRIME Study. This significant milestone comes after Neuralink obtained approval from an independent institutional review board and a hospital site. After receiving FDA approval in May for their first in-human clinical study, Neuralink is ready to take the next step towards the market.
The PRIME Study requires patients to undergo invasive brain surgery. Neuralink is currently developing a brain implant that will enable individuals with severe paralysis to control external technologies using neural signals. Its ultimate goal is to help patients with degenerative diseases like ALS regain their ability to communicate by moving cursors and typing with their minds.
“The initial goal of our brain-computer interface (BCI) is to grant people the ability to control a computer cursor or keyboard using their thoughts alone,” mentioned Neuralink in their blog post.
Neuralink is part of the growing BCI industry, which focuses on decoding brain signals and translating them into commands for external devices. While other companies in this field have developed promising systems, Neuralink stands out due to its association with Elon Musk, the CEO of Tesla and SpaceX.
Although no BCI company has yet received FDA approval, Neuralink’s clearance to recruit patients for a study brings it closer to achieving that milestone.
Denial of responsibility! Vigour Times is an automatic aggregator of Global media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, and all materials to their authors. For any complaint, please reach us at – [email protected]. We will take necessary action within 24 hours.
